1. Home
  2. NAK vs SVRA Comparison

NAK vs SVRA Comparison

Compare NAK & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Northern Dynasty Minerals Ltd.

NAK

Northern Dynasty Minerals Ltd.

HOLD

Current Price

$2.00

Market Cap

918.4M

ML Signal

HOLD

SVRA

Savara Inc.

HOLD

Current Price

$5.64

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NAK
SVRA
Founded
1983
2007
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
918.4M
1.1B
IPO Year
2002
2009

Fundamental Metrics

Financial Performance
Metric
NAK
SVRA
Price
$2.00
$5.64
Analyst Decision
Strong Buy
Buy
Analyst Count
2
9
Target Price
$2.50
$7.33
AVG Volume (30 Days)
8.8M
1.4M
Earning Date
05-11-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$430.87
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.73
$1.89
52 Week High
$2.98
$7.01

Technical Indicators

Market Signals
Indicator
NAK
SVRA
Relative Strength Index (RSI) 71.29 51.47
Support Level $1.83 $5.47
Resistance Level $2.37 $6.10
Average True Range (ATR) 0.12 0.28
MACD 0.07 0.04
Stochastic Oscillator 98.74 57.55

Price Performance

Historical Comparison
NAK
SVRA

About NAK Northern Dynasty Minerals Ltd.

Northern Dynasty Minerals Ltd is a mineral exploration company. It has a single operating segment of acquisition, exploration, and development of mineral properties. Its core asset is the Pebble Project located in Alaska, USA. The Pebble project is seeking to develop a deposit of copper, gold, molybdenum, and silver into a modern mining operation.

About SVRA Savara Inc.

Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

Share on Social Networks: